JP4912885B2 - 酵母におけるｈｐｖ５８ｌ１の最適化発現 - Google Patents

酵母におけるｈｐｖ５８ｌ１の最適化発現 Download PDF

Info

Publication number
JP4912885B2
JP4912885B2 JP2006539751A JP2006539751A JP4912885B2 JP 4912885 B2 JP4912885 B2 JP 4912885B2 JP 2006539751 A JP2006539751 A JP 2006539751A JP 2006539751 A JP2006539751 A JP 2006539751A JP 4912885 B2 JP4912885 B2 JP 4912885B2
Authority
JP
Japan
Prior art keywords
hpv58
yeast
protein
sequence
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006539751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500019A (ja
Inventor
ブライアン，ジヤニン・テイ
ブラウンロウ，ミシエル・ケイ
シユルツ，ローレン・デイー
ワン，シン−ミン
ヤンセン，カトリーン・ウー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2008500019A publication Critical patent/JP2008500019A/ja
Application granted granted Critical
Publication of JP4912885B2 publication Critical patent/JP4912885B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2006539751A 2003-11-12 2004-11-10 酵母におけるｈｐｖ５８ｌ１の最適化発現 Expired - Lifetime JP4912885B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51921103P 2003-11-12 2003-11-12
US60/519,211 2003-11-12
PCT/US2004/037372 WO2005047315A2 (en) 2003-11-12 2004-11-10 Optimized expression of hpv 58 l1 in yeast

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011268598A Division JP5616879B2 (ja) 2003-11-12 2011-12-08 酵母におけるｈｐｖ５８ｌ１の最適化発現

Publications (2)

Publication Number Publication Date
JP2008500019A JP2008500019A (ja) 2008-01-10
JP4912885B2 true JP4912885B2 (ja) 2012-04-11

Family

ID=34590374

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006539751A Expired - Lifetime JP4912885B2 (ja) 2003-11-12 2004-11-10 酵母におけるｈｐｖ５８ｌ１の最適化発現
JP2011268598A Expired - Lifetime JP5616879B2 (ja) 2003-11-12 2011-12-08 酵母におけるｈｐｖ５８ｌ１の最適化発現

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011268598A Expired - Lifetime JP5616879B2 (ja) 2003-11-12 2011-12-08 酵母におけるｈｐｖ５８ｌ１の最適化発現

Country Status (32)

Country Link
US (2) US7498036B2 (enExample)
EP (1) EP1687329B8 (enExample)
JP (2) JP4912885B2 (enExample)
KR (1) KR101170654B1 (enExample)
CN (1) CN1942583B (enExample)
AR (1) AR046835A1 (enExample)
AT (1) ATE452977T1 (enExample)
AU (1) AU2004290032B2 (enExample)
BE (1) BE2015C070I2 (enExample)
BR (1) BRPI0416393B1 (enExample)
CA (1) CA2543928C (enExample)
CY (2) CY1113875T1 (enExample)
DE (1) DE602004024821D1 (enExample)
DK (1) DK1687329T3 (enExample)
ES (1) ES2340287T3 (enExample)
FR (1) FR15C0081I2 (enExample)
HU (1) HUS1500064I1 (enExample)
IL (1) IL175353A (enExample)
IS (1) IS2741B (enExample)
LT (1) LTC1687329I2 (enExample)
LU (1) LU92901I2 (enExample)
MY (1) MY139500A (enExample)
NL (1) NL300775I1 (enExample)
NO (3) NO340633B1 (enExample)
NZ (1) NZ546697A (enExample)
PL (1) PL1687329T3 (enExample)
PT (1) PT1687329E (enExample)
RU (1) RU2370538C2 (enExample)
SI (1) SI1687329T1 (enExample)
TW (1) TWI332988B (enExample)
WO (1) WO2005047315A2 (enExample)
ZA (1) ZA200603106B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US8206950B2 (en) 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
DK1730175T3 (da) 2004-03-24 2010-08-23 Merck Sharp & Dohme Geoptimaliseerde expressie van HPV 52 L1 in gist
US20070243587A1 (en) * 2006-04-14 2007-10-18 Healthbanks Biotech Co., Ltd. Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
CN101148661B (zh) * 2006-09-18 2013-01-02 中国医学科学院基础医学研究所 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
US7709010B2 (en) * 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
CN101293918B (zh) 2007-04-29 2013-03-27 北京万泰生物药业股份有限公司 截短的人乳头瘤病毒16型l1蛋白
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
US8748127B2 (en) * 2007-05-29 2014-06-10 Xiamen University Truncated L1 protein of human papillomavirus type 6
CN101113417B (zh) * 2007-06-22 2011-04-27 山东大学 Hpv基因酵母体外翻译系统的建立
CN101200696B (zh) * 2007-11-14 2011-07-20 山东大学 人乳头瘤病毒的酵母增殖模型及建立方法与应用
EP2479186B1 (en) * 2007-11-23 2015-08-12 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma viruses
KR20090073987A (ko) * 2007-12-31 2009-07-03 정운원 인간유두종바이러스 유전자형 검사를 위한 프라이머, 프로브 및 이를 포함하는 ｄｎａ칩, 이의 검사 방법 및 검사 키트
ES2565846T3 (es) * 2008-05-26 2016-04-07 Cadila Healthcare Limited Vacuna combinada contra el sarampión-papiloma humano
US9335868B2 (en) * 2008-07-31 2016-05-10 Apple Inc. Capacitive sensor behind black mask
WO2011149897A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN101857870B (zh) * 2010-06-12 2012-09-05 上海泽润生物科技有限公司 Hpv58 l1基因及载体、菌株和表达方法
BR112013000996B1 (pt) 2010-07-16 2021-08-10 Xiamen Innovax Biotech Co., Ltd. Proteína l1 hpv58 truncada, ácido nucléico isolado, vetor, célula hospedeira, partícula do tipo viral hpv58, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv58 truncada, método para preparar a partícula do tipo viral hpv58, método para preparar uma vacina, e uso da proteína l1 hpv58 truncada
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
AU2012270418B2 (en) * 2011-06-15 2015-08-13 Posvax Co., Ltd Method for enhancing the production yield of human papillomavirus L1 protein
CN103361280B (zh) * 2012-03-28 2018-07-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
AU2013272283B2 (en) 2012-06-07 2018-02-15 The Children's Hospital Of Philadelphia Controlled gene expression methods
CN103992395B (zh) * 2013-02-18 2018-07-27 北京康乐卫士生物技术股份有限公司 重组hpv-58型l1的vlp疫苗及其制备方法
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN110592133A (zh) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CN104164373B (zh) * 2013-05-17 2019-04-02 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv68l1蛋白的方法
WO2015057541A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
BR112017004181A2 (pt) * 2014-09-11 2017-12-05 Cadila Healthcare Ltd ?gene, vetor, célula hospedeira, partículas similares a vírus, vacina para vírus de papiloma humano, composição imunogênica, adjuvante, método para o preparo de uma vacina de papiloma humano, proteína de capsídeo principal e proteína hpv l1?
CN117187263A (zh) * 2015-03-30 2023-12-08 上海泽润生物科技有限公司 重组人乳头瘤病毒33亚型蛋白表达
CN104878022A (zh) * 2015-04-27 2015-09-02 段青姣 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
CN106831961B (zh) * 2015-12-04 2019-11-05 厦门大学 一种人乳头瘤病毒58型l1蛋白的突变体
CR20220395A (es) 2020-02-14 2022-10-27 Merck Sharp & Dome Llc Vacuna contra hpv
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) * 2021-06-07 2023-03-31 郑州大学 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
EP4380615A1 (en) 2021-08-06 2024-06-12 Merck Sharp & Dohme LLC Hpv vaccine
EP4387660A1 (en) 2021-08-19 2024-06-26 Merck Sharp & Dohme LLC Thermostable lipid nanoparticle and methods of use thereof
US20240408188A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines
CN117054647A (zh) * 2023-07-17 2023-11-14 广东省一鼎生物技术有限公司 一种检测HPV IgG抗体试剂盒及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511010A (ja) * 1999-08-25 2003-03-25 メルク エンド カムパニー インコーポレーテッド ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子
JP2003512031A (ja) * 1999-10-15 2003-04-02 メルク エンド カムパニー インコーポレーテッド 改善された特性を有するヒトパピローマウイルスウイルス様粒子の新規製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821087A (en) 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
DE69836206T2 (de) 1997-02-07 2007-08-23 Merck & Co., Inc. Synthetische hiv gag gene
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
JP4440471B2 (ja) * 1998-08-14 2010-03-24 メルク エンド カムパニー インコーポレーテッド ヒトパピローマウイルスのウイルス様粒子の精製方法
EP1105157B1 (en) 1998-08-14 2006-11-02 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
SE514982C2 (sv) * 1999-09-30 2001-05-28 Active Biotech Ab Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2002008435A1 (en) 2000-07-21 2002-01-31 Glaxo Group Limited Codon-optimized papilloma virus sequences
WO2003068993A1 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
ATE546529T1 (de) 2003-03-24 2012-03-15 Merck Sharp & Dohme Optimierte expression von hpv 31 l1 in hefe
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511010A (ja) * 1999-08-25 2003-03-25 メルク エンド カムパニー インコーポレーテッド ヒト細胞中での発現用に最適化された合成ヒトパピローマウイルス遺伝子
JP2003512031A (ja) * 1999-10-15 2003-04-02 メルク エンド カムパニー インコーポレーテッド 改善された特性を有するヒトパピローマウイルスウイルス様粒子の新規製造方法

Also Published As

Publication number Publication date
CY1113875T1 (el) 2016-06-22
NZ546697A (en) 2009-05-31
HUS1500064I1 (hu) 2016-02-29
TWI332988B (en) 2010-11-11
PL1687329T3 (pl) 2010-06-30
WO2005047315A3 (en) 2006-09-28
TW200519203A (en) 2005-06-16
CN1942583A (zh) 2007-04-04
CA2543928C (en) 2011-04-05
JP2012095652A (ja) 2012-05-24
LU92901I2 (fr) 2016-03-08
IS8425A (is) 2006-04-21
DE602004024821D1 (de) 2010-02-04
US20070036824A1 (en) 2007-02-15
US7976848B2 (en) 2011-07-12
AU2004290032A1 (en) 2005-05-26
AU2004290032B2 (en) 2009-02-05
ES2340287T3 (es) 2010-06-01
BRPI0416393B1 (pt) 2021-06-29
CN1942583B (zh) 2010-10-27
CY2015051I2 (el) 2016-06-22
US20100272749A1 (en) 2010-10-28
ZA200603106B (en) 2007-09-26
EP1687329A2 (en) 2006-08-09
WO2005047315A2 (en) 2005-05-26
DK1687329T3 (da) 2010-04-12
NO2017058I1 (no) 2017-11-10
NL300775I2 (enExample) 2015-12-29
JP5616879B2 (ja) 2014-10-29
NO20062674L (no) 2006-06-09
IS2741B (is) 2011-06-15
RU2006120402A (ru) 2007-12-27
EP1687329B1 (en) 2009-12-23
AR046835A1 (es) 2005-12-28
RU2370538C2 (ru) 2009-10-20
FR15C0081I2 (fr) 2016-11-25
FR15C0081I1 (fr) 2016-08-01
JP2008500019A (ja) 2008-01-10
BE2015C070I2 (enExample) 2023-12-18
IL175353A (en) 2010-11-30
PT1687329E (pt) 2010-02-26
LTC1687329I2 (lt) 2017-05-10
IL175353A0 (en) 2006-09-05
NO340633B1 (no) 2017-05-15
NO2022052I1 (no) 2022-11-30
MY139500A (en) 2009-10-30
SI1687329T1 (sl) 2010-03-31
KR20060122852A (ko) 2006-11-30
BRPI0416393A (pt) 2007-04-03
CA2543928A1 (en) 2005-05-26
US7498036B2 (en) 2009-03-03
CY2015051I1 (el) 2016-06-22
EP1687329B8 (en) 2010-03-17
KR101170654B1 (ko) 2012-08-03
ATE452977T1 (de) 2010-01-15
NL300775I1 (enExample) 2015-12-29

Similar Documents

Publication Publication Date Title
JP5616879B2 (ja) 酵母におけるｈｐｖ５８ｌ１の最適化発現
US7482015B2 (en) Optimized expression of HPV 45 L1 in yeast
US7744892B2 (en) Optimized expression of HPV 52 L1 in yeast
JP4505452B2 (ja) 酵母におけるｈｐｖ３１ｌ１の最適化発現

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100812

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111208

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120110

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120118

R150 Certificate of patent or registration of utility model

Ref document number: 4912885

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150127

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150127

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250